Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CNS
Biotech
UCB-Novartis Parkinson's asset fails to improve symptoms in ph. 2
UCB’s Novartis-partnered oral small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2 trial.
Gabrielle Masson
Dec 16, 2024 3:19pm
With 4 remaining staffers, CNS-focused Trevena nears end of road
Nov 7, 2024 10:40am
Medidata boosts CNS trials with Cogstate's cognitive assessments
Oct 29, 2024 2:40pm
Tiziana prioritizes lowest hanging fruit, shelves unripe assets
Nov 10, 2022 2:56pm
Biohaven fuels up for post-Pfizer future with $302M
Nov 9, 2022 9:55am
UCB offers $370M and plans NDA for Proximagen’s epilepsy spray
Apr 20, 2018 10:31am
